NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Ora... ( SOPHIA ANTIPOLIS France September...)

NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules

Date:9/23/2008

SOPHIA ANTIPOLIS, France, September 23 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced it has signed an exclusive agreement with Capsugel, the leading producer of two-piece capsules, for the commercial manufacturing and global supply of naproxcinod capsules. Naproxcinod is NicOx' lead investigational product and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents. The aim of this agreement is to ensure sufficient supplies of naproxcinod capsules to underpin its successful commercial launch. The filing of a New Drug Application (NDA) for naproxcinod with the U.S. Food and Drug Administration (FDA) is projected for mid-2009.

The agreement with Capsugel follows the signature of an agreement for the commercial manufacture and supply of naproxcinod active pharmaceutical ingredient (API) with Archimica in March 2008. NicOx recently announced the results of the second pivotal phase 3 study for naproxcinod in patients with osteoarthritis of the knee (the 302 study, see NicOx press release of September 15th, 2008). This study met all three of its co-primary efficacy endpoints and supported naproxcinod's non-detrimental effect on blood pressure.

Staffan Stromberg, Vice President of Technical Development and Operations at NicOx, said: "We are very happy to have concluded this agreement with Capsugel, which is recognized as the world leader in capsule manufacturing. We believe Capsugel's flexibility and production capacity is well adapted to NicOx' launch preparations for naproxcinod. This agreement is also the result of the excellent collaboration between the two companies, in which Capsugel's technology has been used in the production of naproxcinod clinical trial supplies."

Under the terms of this exclusive agreement, Capsugel will be responsible for the formulation and encapsulation of naproxcinod API, using its patented LEMS(TM) technology (Liquid Encapsul
'/>"/>

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. NicOx Announces Departure of Damian Marron for CEO Position
2. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
3. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
4. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
5. NicOx Opens U.S. Headquarters in New Jersey
6. Martek Signs Multi-Year Sole-Source Supply Agreement With Hero
7. Assay Designs(TM), Inc. and the Spinal Muscular Atrophy Foundation Announce Collaboration To Accelerate the Discovery of New Therapeutics for Spinal Muscular Atrophy (SMA)
8. Sigma-Aldrich Signs Exclusive Agreement With IsoSciences, LLC, to Distribute Isotopically Labeled Bioactive Compounds
9. BioNeutral Signs Agreement With a Non-profit for Long-Term Removal of Formaldehyde to Save 10,000 Mobile Homes in Louisiana
10. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
11. Lumidigm Signs Strategic Agreement with Methode Electronics : Automotive Supplier Invests in Biometric Component Development

Post Your Comments:

NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Ora...( SOPHIA ANTIPOLIS France September...)